These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1115 related articles for article (PubMed ID: 2749491)

  • 1. Chemosensitization by chlorpromazine (CPZ) and caffeine (C) in human melanoma xenografts sensitive or resistant to methyl-CCNU (semustine).
    Osieka R; Glatte P; Schmidt CG
    Strahlenther Onkol; 1989 Jul; 165(7):526-8. PubMed ID: 2749491
    [No Abstract]   [Full Text] [Related]  

  • 2. Enhancement of semustine-induced cytotoxicity by chlorpromazine and caffeine in a human melanoma xenograft.
    Osieka R; Glatte P; Pannenbäcker R; Schmidt CG
    Cancer Treat Rep; 1986 Oct; 70(10):1167-71. PubMed ID: 3756939
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of methyl-CCNU and procarbazine in advanced malignant melanoma resistant to DTIC therapy.
    Didolkar MS; Baffi RR; Catane R; Kaufman J; Holyoke ED
    Cancer Treat Rep; 1977 Dec; 61(9):1738-9. PubMed ID: 597824
    [No Abstract]   [Full Text] [Related]  

  • 4. Therapeutic potentiation of nitrosoureas using chlorpromazine and caffeine in the treatment of murine tumors.
    Rose WC; Trader MW; Dykes DJ; Laster WR; Schabel FM
    Cancer Treat Rep; 1978 Dec; 62(12):2085-93. PubMed ID: 751716
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized trial of chlorpromazine, caffeine, and methyl-CCNU in disseminated melanoma.
    Cohen MH; Schoenfeld D; Wolter J
    Cancer Treat Rep; 1980 Jan; 64(1):151-3. PubMed ID: 6991102
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Enhancement of MeCCNU potency (chemosensitization) by misonidazole in a human melanoma xenograft system].
    Osieka R; Glatte P; Haedecke U; Schmidt CG
    Strahlentherapie; 1982 Oct; 158(10):620-9. PubMed ID: 7179344
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Combination chemotherapy of transplanted rat leukemia L 5222 with 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU) and cyclophosphamide (CPA) as well as with methyl-CCNU and CPA (author's transl)].
    Zeller WJ; Berger M
    Arzneimittelforschung; 1981; 31(2):303-5. PubMed ID: 7194646
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of a new nitrosoureido water-soluble sugar, ecomustine or CY 233 (NSC 609224), on human xenografts.
    Dumont P; Atassi G; Roger P
    In Vivo; 1990; 4(1):61-4. PubMed ID: 2103843
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The combination of methyl-CCNU and irradiation: cell survival studies on a human tumor xenograft.
    Bateman AE; Fu KK; Towse GD
    Int J Radiat Oncol Biol Phys; 1979 Sep; 5(9):1545-8. PubMed ID: 536260
    [No Abstract]   [Full Text] [Related]  

  • 10. DNA cross-linking by in vivo treatment with 1-(2-chloroethyl)-3-(4-methylcyclohexyl)-1-nitrosourea of sensitive and resistant human colon carcinoma xenograms in nude mice.
    Thomas CB; Osieka R; Kohn KW
    Cancer Res; 1978 Aug; 38(8):2448-54. PubMed ID: 667842
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nitrosoureas in the management of disseminated malignant melanoma.
    Ahmann DL
    Cancer Treat Rep; 1976 Jun; 60(6):747-51. PubMed ID: 782696
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative study of methyl-CCNU (NSC-95441) with cyclophosphamide (NSC-26271) and 5-(3,3-dimethyl-1-triazeno)imidazole-4-carboxamide (NSC-45388) with vincristine (NSC-67574) in patients with disseminated malignant melanoma.
    Ahmann DL; Hahn RG; Bisel HF; Eagan RT; Edmonson JH
    Cancer Chemother Rep; 1975; 59(2 Pt 1):451-3. PubMed ID: 1097102
    [No Abstract]   [Full Text] [Related]  

  • 13. Therapeutic evaluation of five nitrosoureas in a human melanoma xenograft system.
    Osieka R; Glatte P; Pannenbäcker R; Schmidt CG
    Cancer Chemother Pharmacol; 1983; 11(3):147-52. PubMed ID: 6227420
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vivo drug sensitivity assay of clonogenic human melanoma cells and correlation with treatment outcome.
    Kirkwood JM; Marsh JC
    Cancer Res; 1983 Jul; 43(7):3434-40. PubMed ID: 6850650
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vivo chemosensitization by misonidazole in sensitive and resistant tumor lines.
    Mulcahy RT; Siemann DW
    Cancer Res; 1983 Oct; 43(10):4709-13. PubMed ID: 6883329
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Methyl-CCNU inclinical cancer therapy.
    Wasserman TH; Slavik M; Carter SK
    Cancer Treat Rev; 1974 Dec; 1(4):251-69. PubMed ID: 4377543
    [No Abstract]   [Full Text] [Related]  

  • 17. Methyl-CCNU for patients with previously treated metastatic neuroblastoma--a phase II study.
    Evans AE; Bernstein I; Finklestein J; Klemperer M; Leikin S; Weiner JM; Hammond GD
    Cancer Treat Rep; 1977; 61(1):83-5. PubMed ID: 324623
    [No Abstract]   [Full Text] [Related]  

  • 18. Results with methyl-CCNU and DTIC in metastatic melanoma.
    Costanza ME; Nathanson L; Schoenfeld D; Wolter J; Colsky J; Regelson W; Cunningham T; Sedransk N
    Cancer; 1977 Sep; 40(3):1010-5. PubMed ID: 332319
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Immuno-chemotherapy in patients with disseminated metastasizing stage III melanoma. Randomized study with methyl-CCNU versus C. parvum plus methyl-CCNU].
    Kokoschka EM; Luger T; Micksche M
    Onkologie; 1978 Jun; 1(3):98-103. PubMed ID: 362293
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomized trial of chlorozotocin, neocarzinostatin, or methyl-CCNU in patients with malignant melanoma.
    Von Hoff DD; Amato DA; Kaufman JH; Falkson G; Cunningham TJ
    Am J Clin Oncol; 1984 Apr; 7(2):135-9. PubMed ID: 6230929
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 56.